NEUPNeuphoria Therapeutics Inc.

Sign up free
Thesis

Neuphoria is merging into Scancell, whose iSCIB1+ showed 77% 22-month PFS with ipilimumab and nivolumab in melanoma

Thesis as of Jul 23, 2026

Neuphoria Therapeutics, whose BNC210 missed its Phase 3 endpoints in social anxiety disorder, has agreed to an all-share merger into Scancell, whose lead candidate iSCIB1+ is in development for advanced melanoma.

Neuphoria agreed to an all-share merger with Scancell, with the combined company to list on Nasdaq as SCLT, expected late in the fourth quarter of 2026. Its value would then rest on Scancell's iSCIB1+, an immunotherapy that showed 77% progression-free survival at 22 months when given with ipilimumab and nivolumab in the Phase 2 SCOPE study in advanced melanoma. Scancell plans a registrational Phase 3 with a primary readout in the second half of 2028. Neuphoria's own BNC210 missed its Phase 3 endpoints in social anxiety disorder.

Status
Challenged

Approvability unresolved — Phase 3 readout H2 2028

Conviction

Current Thesis Drivers

  • Phase 2 SCOPE: 77% PFS at 22 months in advanced melanoma
  • Approvability unresolved — Phase 3 readout H2 2028
  • BNC-210 Phase 3 AFFIRM-1 missed all endpoints in SAD
  • Merck discontinued Neuphoria small molecule Phase 2 in Alzheimer's

What could change the thesis?

  • Phase 2 OS/PFS update: confirms durability reopens bull case, miss deflates Phase 3 confidence
  • Merger/Nasdaq SCLT close: completion de-risks structure; failure disrupts financing and timelines
  • BlackRock $25M debt finalization: converts term sheet, bolsters runway; falls through tightens cash

Generated from public SEC filings and disclosures. For informational purposes only — not investment advice. Always conduct your own research before making investment decisions.

Thesis log

Tracked in real time as it happened — not reconstructed after the fact

Key value driver

The most decisive event ahead

Bull and bear case

Both sides of the Thesis, argued

Pipeline

2 programs · 5 catalysts

Quick answers

Is the Neuphoria Therapeutics (NEUP) investment thesis intact?
It is under pressure. Readouts currently rates the Neuphoria Therapeutics Thesis Challenged. Neuphoria is merging into Scancell, whose iSCIB1+ showed 77% 22-month PFS with ipilimumab and nivolumab in melanoma.
How long will Neuphoria Therapeutics' cash last?
Neuphoria Therapeutics has said its cash will fund operations beyond the second quarter of fiscal year 2028 (guidance as of September 18, 2026).

Other companies we cover in these diseases

Social anxiety disorder
Cingulate (CING)

Disease areas: Other cancers, Psychiatric disorders
Catalyst calendar · Upcoming FDA decisions · Thesis changes

Stress Test